BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Ociperlimab Update

More Like This

BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024

(Graphic: Business Wire)

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer